StreetInsider.com News Articles

Goldman Sachs Reiterates Buy Rating on Latigo Biotherapeutics (LTGO)

Mon, 14 Sep 2026 07:53:06 -0400

Goldman Sachs analyst Salveen Richter reiterated a Buy rating and $73.00 price target on Latigo Biotherapeutics (NASDAQ: LTGO)

For an analyst ratings summary and ratings history on Latigo Biotherapeutics click here. For more ratings news on Latigo Biotherapeutics click here.

Shares of Latigo Biotherapeutics closed at $22.15 yesterday.

Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Thu, 03 Sep 2026 16:05:00 -0400

Completed upsized initial public offering, including full exercise of the underwriters’ option to purchase additional shares, raising gross proceeds of $397.4 million; together with existing cash expected to fund operations into 2029

The New England Journal of Medicine published positive onzotrigine (previously referred to as LTG-001) abdominoplasty clinical trial results in moderate-to-severe acute pain

Expanded leadership team with appointment of Naomi Lowy, M.D., former deputy director of the FDA Division of Anesthesia, Addiction Medicine, and Pain Medicine, as senior vice president of global regulatory affairs

THOUSAND OAKS, Calif., Sept. 03, 2026

Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Thu, 03 Sep 2026 16:05:00 -0400

The New England Journal of Medicine published positive onzotrigine (previously referred to as LTG-001) abdominoplasty clinical trial results in moderate-to-severe acute pain

THOUSAND OAKS, Calif., Sept. 03, 2026

Jefferies Starts Latigo Biotherapeutics (LTGO) at Buy

Tue, 01 Sep 2026 06:16:56 -0400

Jefferies analyst Akash Tewari initiates coverage on Latigo Biotherapeutics (NASDAQ: LTGO) with a Buy rating and a price target of $50.00.

The analyst comments "We're initiating on LTGO w/ a Buy & $50 PT: 1) We believe LTG-001 will show at least as good SPID48 as SUZ in Ph3 bunionectomy study & faster onset. While not base case, we see signs for pot'ly better pbo-adj SPID48; 2) Although early, we’re encouraged by LTG-321 for OA chronic pain; 3) pain market is large w/ room for >1 Nav1.8. We est $1.2Bn risk-adj PS for '001 in acute pain (70% POS) w/ optionality

Jefferies Starts Latigo Biotherapeutics (LTGO) at Buy

Tue, 01 Sep 2026 06:16:56 -0400

Jefferies analyst Akash Tewari initiates coverage on Latigo Biotherapeutics (NASDAQ: LTGO) with a Buy rating and a price target of $50.00.

Jefferies Starts Latigo Biotherapeutics (LTGO) at Buy

Tue, 01 Sep 2026 06:16:56 -0400

Jefferies analyst Akash Tewari initiates coverage on Latigo Biotherapeutics (NASDAQ: LTGO) with a Buy rating and a price target of $50.00.

Jefferies Starts Latigo Biotherapeutics (LTGO) at Buy

Tue, 01 Sep 2026 06:16:56 -0400

Jefferies analyst Akash Tewari initiates coverage on Latigo Biotherapeutics (NASDAQ: LTGO) with a Buy rating and a price target of $50.00.

Leerink Starts Latigo Biotherapeutics (LTGO) at Outperform

Tue, 01 Sep 2026 06:11:29 -0400

Leerink analyst David Risinger initiates coverage on Latigo Biotherapeutics (NASDAQ: LTGO) with a Outperform rating and a price target of $36.00.

For an analyst ratings summary and ratings history on Latigo Biotherapeutics click here. For more ratings news on Latigo Biotherapeutics click here.

Shares of Latigo Biotherapeutics closed at $22.02 yesterday.

Guggenheim Starts Latigo Biotherapeutics (LTGO) at Buy

Tue, 01 Sep 2026 03:38:55 -0400

Guggenheim analyst Yatin Suneja initiates coverage on Latigo Biotherapeutics (NASDAQ: LTGO) with a Buy rating and a price target of $50.00.

The analyst comments: “We initiate coverage of Latigo Biotherapeutics, Inc. (LTGO) at BUY with a $50 price target — implying ~127% upside to the closing price — driven by two 2H'27 binary catalysts and second-mover economics in a class Vertex has already commercially validated (Journavx: >900K Rx in 1H26; >260M covered lives). LTG-001 (Ph3-ready, acute pain) delivered a SPID48 of +62.1 vs. placebo (p<0.001) in its Ph2 abdominoplasty trial — ~30% larger than Journavx's +48.4 — with 2.3x faster onset

Guggenheim Starts Latigo Biotherapeutics (LTGO) at Buy

Tue, 01 Sep 2026 03:38:55 -0400

Guggenheim analyst Yatin Suneja initiates coverage on Latigo Biotherapeutics (NASDAQ: LTGO) with a Buy rating and a price target of $50.00.

Goldman Sachs Starts Latigo Biotherapeutics (LTGO) at Buy

Tue, 01 Sep 2026 02:49:00 -0400

Goldman Sachs analyst Salveen Richter initiates coverage on Latigo Biotherapeutics (NASDAQ: LTGO) with a Buy rating and a price target of $73.00.

The analyst comments: “LTGO is a clinical-stage biotechnology company developing non-opioid pain medicines without addictive potential via inhibition of Nav1.8, a target involved in transmitting pain signals. Lead asset LTG-001 in acute pain has demonstrated greater pain relief versus placebo (p<0.001) and an opioid comparator (numerically), and fast onset of pain relief in a Phase 2b study post abdominoplasty which in addition to Phase 3 bunionectomy and safety data in 2H27 should support approval (GSe 2028 launch; peak sales

Goldman Sachs Starts Latigo Biotherapeutics (LTGO) at Buy

Tue, 01 Sep 2026 02:49:00 -0400

Goldman Sachs analyst Salveen Richter initiates coverage on Latigo Biotherapeutics (NASDAQ: LTGO) with a Buy rating and a price target of $73.00.

Latigo Biotherapeutics prices $345.6M IPO at $18 per share